Molecular Partners AGCompany Review & Valuation

MLLCF
OTC Markets

About Molecular Partners AG

Molecular Partners AG, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of various biopharmaceutical products. It is developing Abicipar, a DARPin-based anti-angiogenic drug, which is in Phase III clinical trials for the treatment of wet age-reShow morelated macular degeneration, as well as is in Phase III clinical trials to treat diabetic macular edema diseases; and multi-VEGF/PDGF DARPin that is in preclinical studies for other ocular targets. The company is also developing MP0250, which is in Phase I clinical studies for the treatment of solid tumor cancers and hematological malignancies; and MP0274 that is in preclinical studies for the treatment of breast cancer. The company has strategic partnerships with Allergan, Inc., F. Hoffmann-La Roche Ltd, and Janssen Biotech, Inc. Molecular Partners AG was founded in 2004 and is based in Schlieren, Switzerland.Show less

Industry
Biotechnology
HQ Location
Schlieren, Switzerland

Stock Price

Price data not available for Molecular Partners AG.

Performance

Please login or create a free account to view the contents of this section.

Similar Companies

Kalytera Therapeutics
Advaxis, Inc.
Incyte
RedHill Biopharma

back to top